The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EW | +15.44% | -1.39% | -0.28% | +6,105% |
| S&P | +11.96% | +82.68% | +12.81% | +346% |
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Investors trade on future potential rather than trailing results, and they found the company's top-line guidance wanting.
These companies have consistently delivered revenue and EPS gains.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.55B | 14.7% |
| Gross Profit | $1.22B | 13.2% |
| Gross Margin | 78.29% | -1.0% |
| Market Cap | $45.66B | 14.9% |
| Market Cap / Employee | $2.89M | 0.0% |
| Employees | 15.8K | -20.2% |
| Net Income | $292.30M | -19.3% |
| EBITDA | $472.30M | 14.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.69B | -27.0% |
| Accounts Receivable | $693.30M | -3.2% |
| Inventory | 1.1K | 3.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $673.50M | -1.3% |
| Short Term Debt | $26.80M | 10.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.23% | -2.8% |
| Return On Invested Capital | 18.44% | -2.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $516.20M | 72.1% |
| Operating Free Cash Flow | $573.70M | 63.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 50.78 | 48.43 | 53.39 | 33.11 | -29.04% |
| Price to Book | 4.57 | 4.27 | 4.53 | 4.34 | -18.87% |
| Price to Sales | 7.64 | 7.69 | 8.09 | 7.74 | 15.36% |
| Price to Tangible Book Value | 6.25 | 6.06 | 6.39 | 6.02 | -11.11% |
| Price to Free Cash Flow TTM | 150.79 | 67.29 | 78.21 | 56.64 | -25.91% |
| Enterprise Value to EBITDA | 103.32 | 90.46 | 93.17 | 89.79 | 3.48% |
| Free Cash Flow Yield | 0.7% | 1.5% | 1.3% | 1.8% | 34.97% |
| Return on Equity | 17.2% | 16.7% | 15.7% | 13.6% | -24.22% |
| Total Debt | $700.00M | $699.40M | $702.60M | $700.30M | -0.91% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
